Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics Inc (NQ: APRE )

25.60 -0.40 (-1.54%)
Streaming Delayed Price Updated: 2:04 PM EDT, Oct 27, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 83,860
Open 25.84
Bid (Size) 25.61 (1)
Ask (Size) 25.80 (1)
Prev. Close 26.00
Today's Range 24.90 - 26.39
52wk Range 21.22 - 53.11
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
From GlobeNewswire News Releases
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
From GlobeNewswire News Releases

Performance

YTD
-43.49%
-43.49%
1 Month
+13.02%
+13.02%
3 Month
-5.74%
-5.74%
6 Month
-23.67%
-23.67%
1 Year
+3.06%
+3.06%

More News

Read More
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
From GlobeNewswire News Releases
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
From GlobeNewswire News Releases
Aprea Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
From GlobeNewswire News Releases
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
From GlobeNewswire News Releases
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
From GlobeNewswire News Releases
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia a
From GlobeNewswire News Releases
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
From GlobeNewswire News Releases
Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.